(Q44604732)

4 December 2017

Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival (English)

1 reference

4 December 2017

Gupta D

1

1 reference

4 December 2017

Bronstein IB

series ordinal

2

1 reference

4 December 2017

Holden JA

series ordinal

3

1 reference

4 December 2017

language of work or name

English

0 references

publication date

1 February 2000

1 reference

4 December 2017

1 reference

4 December 2017

31

1 reference

4 December 2017

2

1 reference

4 December 2017

214-219

1 reference

Clinical applications of the camptothecins.

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Phase II trial of irinotecan in patients with metastatic colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin.

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Phase II trial of topotecan in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Prognostic significance of morphologic parameters in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Immunohistochemical staining for DNA topoisomerase II in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Expression of P-glycoprotein and multidrug resistance in renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

The proliferation-associated Ki-67 protein: definition in molecular terms

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

Comparison of DNA topoisomerase IIα expression in small cell and nonsmall cell carcinoma of the lung: In search of a mechanism of chemotherapeutic response

1 reference

https://api.crossref.org/works/10.1016%2FS0046-8177%2800%2980222-1

7 January 2021

10.1016/S0046-8177(00)80222-1

Identifiers

DOI

1 reference

4 December 2017

1 reference